Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of aggressive empiric antibiotic therapy on the emergence of antimicrobial resistance during the treatment of ventilator-associated pneumonia

Trial Profile

Impact of aggressive empiric antibiotic therapy on the emergence of antimicrobial resistance during the treatment of ventilator-associated pneumonia

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Meropenem; Tobramycin; Vancomycin
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top